四君子汤加减联合化疗治疗胃肠道恶性肿瘤多药耐药基因阳性病例

Treatment of Gastrointestinal Cancer Multidrug Resistance Gene-positive Cases by Sijunzitang with Chemotherapy

目的:观察四君子汤加减联合化疗综合治疗胃肠道恶性肿瘤多药耐药基因阳性患者的疗效。方法:采用免疫组化的方法对本院近几年117例胃肠道恶性肿瘤标本予以多药耐药基因的检测,并对其中多药耐药基因阳性的55例患者用四君子汤加减联合化疗进行了治疗研究,其中治疗组28例,用化疗的同时,服用四君子汤加减治疗;对照组27例,只采用化疗。结果:中药加化疗组患者化疗过程中毒副反应明显轻于单纯化疗组,完成化疗率96.4%。单用化疗组由于白细胞减少或消化道反应严重而中止化疗,能完成化疗者只占70.4%;治疗组Ⅰ,Ⅱ,Ⅲ期5年生存期分别为75.0%,63.6%,22.2%,对照组Ⅰ,Ⅱ,Ⅲ期5年生存期分别为55.6%,37.5%,10.0%。结论:四君子汤加减联合化疗对胃肠道恶性肿瘤多药耐药基因阳性病例具有明显的临床疗效。

Objective：To observe the therapeutic effect of Sijunzitang with chemotherapy in treating gastrointestinal cancer multidrug resistance gene-positive patients.Method：By immunohistochemical methods in our hospital 117 cases of gastrointestinal cancer pathology specimens for detection of multidrug resistance gene,and multidrug resistance gene in which 55 patients were positive for clinical studies,treatment group 28 cases,using Sijunzitang combined with chemotherapy for treatment;the control group 27 cases,only with chemotherapy.Result：Toxic side-effects in patients treated by Sijunzitang combined with chemotherapy were significantly lower than that in chemotherapy group,the completion of chemotherapy rate was 96.4%.In chemotherapy alone group,due to neutropenia or serious gastrointestinal response and chemotherapy had been suspended for some cases,to completion rate was only 70.4%.The treatment group Ⅰ,Ⅱ,Ⅲ period of 5 years survival were 75.0%,63.6%,22.2%,while the control group were 55.6%,37.5%,10.0%.Conclusion：Sijunzitang with chemotherapy has definite effect for the treatment of gastrointestinal tract cancer multidrug resistance gene-positive cases.